EMERYVILLE, Calif., Nov. 26,
2024 /PRNewswire/ -- Dynavax Technologies Corporation
(Nasdaq: DVAX), a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines, today
announced that the Company will present at the 7th Annual Evercore
HealthCONx Conference on Tuesday, December
3 at 2:35 p.m. ET.
The presentation will be webcast and may be accessed through the
"Events & Presentations" page on the "Investors" section of the
Company's website at
https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage
biopharmaceutical company developing and commercializing innovative
vaccines to help protect the world against infectious diseases. The
Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis
B Vaccine (Recombinant), Adjuvanted], which is approved in the
U.S., the European Union and Great
Britain for the prevention of infection caused by all known
subtypes of hepatitis B virus in adults 18 years of age and older,
and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple
adjuvanted COVID-19 vaccines. For more information about our
marketed products and development pipeline, visit
www.dynavax.com.
For Investors/Media:
Paul
Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-7th-annual-evercore-healthconx-conference-302315117.html
SOURCE Dynavax Technologies
